Logo image of ALESE.PA

ENTECH SACA (ALESE.PA) Stock Fundamental Analysis

Europe - EPA:ALESE - FR0014004362 - Common Stock

7.72 EUR
-0.08 (-1.03%)
Last: 10/31/2025, 7:00:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALESE. ALESE was compared to 46 industry peers in the Construction & Engineering industry. While ALESE seems to be doing ok healthwise, there are quite some concerns on its profitability. ALESE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALESE has reported negative net income.
In the past year ALESE had a positive cash flow from operations.
ALESE had negative earnings in 4 of the past 5 years.
In the past 5 years ALESE always reported negative operating cash flow.
ALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of ALESE (-3.88%) is worse than 91.30% of its industry peers.
The Return On Equity of ALESE (-11.31%) is worse than 91.30% of its industry peers.
Industry RankSector Rank
ROA -3.88%
ROE -11.31%
ROIC N/A
ROA(3y)-2.34%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALESE.PA Yearly ROA, ROE, ROICALESE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

The Gross Margin of ALESE (42.82%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ALESE has declined.
ALESE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
ALESE.PA Yearly Profit, Operating, Gross MarginsALESE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

ALESE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALESE remains at a similar level compared to 1 year ago.
Compared to 1 year ago, ALESE has a worse debt to assets ratio.
ALESE.PA Yearly Shares OutstandingALESE.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M
ALESE.PA Yearly Total Debt VS Total AssetsALESE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

ALESE has an Altman-Z score of 2.22. This is not the best score and indicates that ALESE is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.22, ALESE is in the better half of the industry, outperforming 67.39% of the companies in the same industry.
The Debt to FCF ratio of ALESE is 1.80, which is an excellent value as it means it would take ALESE, only 1.80 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 1.80, ALESE is doing good in the industry, outperforming 73.91% of the companies in the same industry.
A Debt/Equity ratio of 0.27 indicates that ALESE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.27, ALESE is in the better half of the industry, outperforming 71.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 1.8
Altman-Z 2.22
ROIC/WACCN/A
WACC7.73%
ALESE.PA Yearly LT Debt VS Equity VS FCFALESE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ALESE has a Current Ratio of 1.57. This is a normal value and indicates that ALESE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.57, ALESE belongs to the top of the industry, outperforming 82.61% of the companies in the same industry.
ALESE has a Quick Ratio of 1.51. This is a normal value and indicates that ALESE is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Quick ratio value of 1.51, ALESE belongs to the best of the industry, outperforming 86.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.51
ALESE.PA Yearly Current Assets VS Current LiabilitesALESE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

ALESE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -294.30%.
ALESE shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.45%.
ALESE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 68.95% yearly.
EPS 1Y (TTM)-294.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.21%
Revenue 1Y (TTM)32.45%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%56.95%

3.2 Future

ALESE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 110.19% yearly.
ALESE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.17% yearly.
EPS Next Y119.05%
EPS Next 2Y122.54%
EPS Next 3Y110.19%
EPS Next 5YN/A
Revenue Next Year38.3%
Revenue Next 2Y50.27%
Revenue Next 3Y51.15%
Revenue Next 5Y38.17%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALESE.PA Yearly Revenue VS EstimatesALESE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ALESE.PA Yearly EPS VS EstimatesALESE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

ALESE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 24.18 indicates a rather expensive valuation of ALESE.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALESE indicates a slightly more expensive valuation: ALESE is more expensive than 78.26% of the companies listed in the same industry.
ALESE is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.55, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 24.18
ALESE.PA Price Earnings VS Forward Price EarningsALESE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

69.57% of the companies in the same industry are more expensive than ALESE, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.6
EV/EBITDA N/A
ALESE.PA Per share dataALESE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALESE's earnings are expected to grow with 110.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y122.54%
EPS Next 3Y110.19%

More info and screens

0

5. Dividend

5.1 Amount

ALESE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTECH SACA

EPA:ALESE (10/31/2025, 7:00:00 PM)

7.72

-0.08 (-1.03%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners11.38%
Inst Owner ChangeN/A
Ins Owners63.72%
Ins Owner ChangeN/A
Market Cap113.33M
Revenue(TTM)45.47M
Net Income(TTM)-2921600
Analysts86
Price Target11.63 (50.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-71.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.18
P/S 2.49
P/FCF 8.6
P/OCF 7.99
P/B 4.39
P/tB 5.76
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)0.32
Fwd EY4.14%
FCF(TTM)0.9
FCFY11.63%
OCF(TTM)0.97
OCFY12.51%
SpS3.1
BVpS1.76
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.88%
ROE -11.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.82%
FCFM 28.98%
ROA(3y)-2.34%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
F-Score3
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 1.8
Debt/EBITDA N/A
Cap/Depr -3048.48%
Cap/Sales 2.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.51
Altman-Z 2.22
F-Score3
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)285.26%
Cap/Depr(5y)212.15%
Cap/Sales(3y)7.1%
Cap/Sales(5y)9.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-294.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.21%
EPS Next Y119.05%
EPS Next 2Y122.54%
EPS Next 3Y110.19%
EPS Next 5YN/A
Revenue 1Y (TTM)32.45%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%56.95%
Revenue Next Year38.3%
Revenue Next 2Y50.27%
Revenue Next 3Y51.15%
Revenue Next 5Y38.17%
EBIT growth 1Y-189.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year308.6%
EBIT Next 3Y160.4%
EBIT Next 5Y103.56%
FCF growth 1Y230.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y258.99%
OCF growth 3YN/A
OCF growth 5YN/A

ENTECH SACA / ALESE.PA FAQ

What is the fundamental rating for ALESE stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALESE.PA.


Can you provide the valuation status for ENTECH SACA?

ChartMill assigns a valuation rating of 3 / 10 to ENTECH SACA (ALESE.PA). This can be considered as Overvalued.


What is the profitability of ALESE stock?

ENTECH SACA (ALESE.PA) has a profitability rating of 1 / 10.


Can you provide the financial health for ALESE stock?

The financial health rating of ENTECH SACA (ALESE.PA) is 6 / 10.